Published in PLoS One on September 02, 2015
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol (2016) 0.82
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother (2016) 0.80
Humanization of high-affinity antibodies targeting glypican-3 in hepatocellular carcinoma. Sci Rep (2016) 0.79
Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins (Basel) (2016) 0.78
Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate. Sci Rep (2016) 0.77
Insights into the role of sulfated glycans in cancer cell adhesion and migration through use of branched peptide probe. Sci Rep (2016) 0.76
Recent Insights into Cell Surface Heparan Sulphate Proteoglycans and Cancer. F1000Res (2016) 0.75
Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells. Oncotarget (2016) 0.75
Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem (1999) 11.87
Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res (1982) 11.72
Scatter factor/hepatocyte growth factor is essential for liver development. Nature (1995) 5.91
Hepatocellular carcinoma: clinical frontiers and perspectives. Gut (2014) 5.79
Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A (1998) 4.99
Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature (1995) 4.68
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer (2006) 3.45
Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer (2002) 3.36
TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques (2009) 3.35
Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol (2011) 2.96
Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A (2004) 2.77
Glypicans. Genome Biol (2008) 2.76
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res (2005) 2.68
Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology (2014) 1.87
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol (2009) 1.82
Spherical cancer models in tumor biology. Neoplasia (2015) 1.75
Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res (1999) 1.69
Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res (2014) 1.68
Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res (1997) 1.67
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci (2009) 1.64
Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO J (1997) 1.60
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem (2004) 1.54
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2013) 1.51
Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology (1997) 1.50
Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood (2002) 1.50
Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells. J Clin Invest (2008) 1.43
Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol (2001) 1.34
PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost (2007) 1.24
Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res (2007) 1.24
Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb (2009) 1.16
Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol (2011) 1.14
Met as a therapeutic target in HCC: facts and hopes. J Hepatol (2013) 1.03
PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs (2008) 0.99
Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem (2012) 0.98
Targeted disruption of heparan sulfate interaction with hepatocyte and vascular endothelial growth factors blocks normal and oncogenic signaling. Cancer Cell (2012) 0.95
Hepatocyte growth factor-mediated renal epithelial branching morphogenesis is regulated by glypican-4 expression. Mol Cell Biol (2004) 0.94
Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis. Nat Commun (2015) 0.90
Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front Oncol (2012) 0.86
Glypican-1 regulates myoblast response to HGF via Met in a lipid raft-dependent mechanism: effect on migration of skeletal muscle precursor cells. Skelet Muscle (2014) 0.84
Heparan Sulfate Proteoglycans Regulate Fgf Signaling and Cell Polarity during Collective Cell Migration. Cell Rep (2015) 0.82
Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. World J Gastroenterol (2010) 0.81
Correlation of glypican-1 expression with TGF-beta, BMP, and activin receptors in pancreatic ductal adenocarcinoma. Int J Oncol (2006) 0.81
From minimal to maximal surgery in the treatment of hepatocarcinoma: A review. World J Hepatol (2015) 0.76